Kevan Herold
Chair
Credentials: · · · · · ·
History
Present- Present
- Until 1984
Until 1982- 1979
Jefferson Medical College
Research
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
New England Journal of Medicine · 2002 · First of 11 authors · Corresponding · 943 citations
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Review · Nature · 2010 · 922 citations
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
New England Journal of Medicine · 2019 · First of 22 authors · 918 citations
- CG
35 papers
32 papers
28 papers
25 papers
22 papers
22 papers
17 papers
16 papers
Grants
- 2021–2031
Human and Translational Immunology Training Program
National Institute of Allergy and Infectious Diseases · T32
Contact PI · $2.6M · Yale University
- 2026–2031
Pathogenesis and Assessment of Activity in Celiac Disease (CeD)
National Institute of Allergy and Infectious Diseases · P01
Project lead · $388.8K · Yale University
- 1975–2029
Diabetes Mellitus and Disorders of Metabolism
National Institute of Diabetes and Digestive and Kidney Diseases · T32
PI · $1.1M · Yale University
- 2000–2029
Modulating Pathogenic T Cells in Type 1 Diabetes
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $11.1M · Yale University
Clinical trials
- 2018–2021
Principal investigator · Completed · Phase 1, Phase 2
Precigen Actobio T1D, LLC
- 2014–2016
- 2012–2013
Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes
Principal investigator · Completed · Phase 1
Yale University
- 2010–2017
T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs
Principal investigator · Completed · Phase 1
University of California, San Francisco